EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantitative adverse outcome pathway modeling of cisplatin-induced nephrotoxicity: developing in vitro and in vivo models for predictive extrapolation

Filippo Di Tillio, Lukas S Wijaya, Steven J Kunnen iD, Carl Joshua Eugenio, Giorgio Buzzanca iD, Imke B Bruns, Marvin Martens iD, Nynke I Kramer, Jesper Kers, Giulia Callegaro, Bob van de Water, Joost B Beltman

Toxicological Sciences · 18.02.2026 · 209 (2)

DOI: 10.1093/toxsci/kfaf177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 09.01.2026. Verfasst von Filippo Di Tillio und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333 CC, The Netherlands. Hauptthemen laut MEDLINE: Cisplatin, Antineoplastic Agents, Adverse Outcome Pathways, Kidney. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Research Council, European Union's Horizon-MSCA project SIGNATURE, European Union’s Horizon-MSCA project SIGNATURE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nephrotoxicity is a major concern in the safety assessment of chemicals and drugs. Computational modeling, particularly the use of quantitative adverse outcome pathways (qAOPs), offers a promising strategy to improve the translation from in vitro to in vivo, thereby facilitating reliable predictions of in vivo adverse outcomes and potentially reducing the need for animal testing. Platinum-based drugs are widely used in chemotherapy, yet their clinical application is frequently constrained by nephrotoxic effects. Here, we focus on the development of ordinary differential equation (ODE)-based qAOPs for platinum-induced nephrotoxicity by defining both an in vitro and an in vivo data-driven model. The in vitro model incorporates newly generated, time-course gene expression and propidium iodide (PI) staining data from RPTEC/TERT1 cells exposed to cisplatin. The in vivo model employs published rat data, including dose-response platinum kinetics as well as single-dose time-course platinum kinetics, gene expression, and histopathology data. Our quantitative approach shows that key processes in the AOP related to immune system activity are nonlinear. Specifically, clearance of necrotic kidney cells by immune system activity counters damage accumulation on a timescale of days, yet low-level inflammation still cumulatively affects kidney failure in the long run. Moreover, we perform quantitative in vitro to in vivo extrapolation (QIVIVE) to link the 2 models. With this approach, in vivo adverse outcome predictions can be made in the future not only for platinum-based compounds but also for the safety assessment of other chemicals and drugs, reducing the need for animal testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinAntineoplastic AgentsAdverse Outcome PathwaysKidneyKidney DiseasesModels, BiologicalAnimalsCell LineHumansRatsDose-Response Relationship, Drug

Stichwörter der Autor:innen

ODEscisplatinqAOP

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333 CC, The Netherlands.
  • Department of Pathology, Leiden University Medical Center, Leiden, 2300 RC, The Netherlands.
  • Department of Translational Genomics, NUTRIM, Maastricht University, Maastricht, 6229 ER, The Netherlands.
  • Department of Toxicology, Wageningen University, Wageningen, 6708 WE, The Netherlands.
  • Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, 1081 HV, The Netherlands.

ORCID-Profile: Steven J Kunnen, Giorgio Buzzanca, Marvin Martens

Förderung

  • Netherlands Research Council
  • European Union's Horizon-MSCA project SIGNATURE
  • European Union’s Horizon-MSCA project SIGNATURE

Zitieren

APA

Di Tillio, F., Wijaya, L. S., Kunnen, S. J., Eugenio, C. J., Buzzanca, G., Bruns, I. B., Martens, M., Kramer, N. I., Kers, J., Callegaro, G., van de Water, B., & Beltman, J. B. (2026). Quantitative adverse outcome pathway modeling of cisplatin-induced nephrotoxicity: developing in vitro and in vivo models for predictive extrapolation. Toxicological Sciences, 209(2). https://doi.org/10.1093/toxsci/kfaf177

Vancouver

Di Tillio F, Wijaya LS, Kunnen SJ, Eugenio CJ, Buzzanca G, Bruns IB, et al. Quantitative adverse outcome pathway modeling of cisplatin-induced nephrotoxicity: developing in vitro and in vivo models for predictive extrapolation. Toxicological Sciences. 2026;209(2). doi:10.1093/toxsci/kfaf177

BibTeX
@article{DiTillio2026,
  author = {Di Tillio, Filippo and Wijaya, Lukas S and Kunnen, Steven J and Eugenio, Carl Joshua and Buzzanca, Giorgio and Bruns, Imke B and Martens, Marvin and Kramer, Nynke I and Kers, Jesper and Callegaro, Giulia and van de Water, Bob and Beltman, Joost B},
  title = {Quantitative adverse outcome pathway modeling of cisplatin-induced nephrotoxicity: developing in vitro and in vivo models for predictive extrapolation},
  journal = {Toxicological Sciences},
  year = {2026},
  volume = {209},
  number = {2},
  doi = {10.1093/toxsci/kfaf177}
}
Kostenlos starten →